ClinicalTrials.gg

Program

Imlunestrant

Also written as “LY3484356”, “Imlunestrant (Test)” and “Imlunestrant (Reference)”.

Its studies are mostly in Breast Neoplasms · Hepatic Insufficiency, led by Eli Lilly.

Furthest: phase 3, since Jul 22, 202112 company-led studies, 6 open or runningNext primary completion: Aug 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly126 open or runningphase 3since Jul 22, 2021Nov 18, 2019Aug 2027phase 1 · NCT07918859

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 18, 2019First study: phase 1 study in Breast NeoplasmsFirst studyNCT04188548 · 379 enrolled · United States, Australia, Belgium and more
  2. Nov 30, 2020Phase 1 study in Breast NeoplasmsNCT04647487 · 87 enrolled · United States, Belgium, France and more
  3. Apr 9, 2021Phase 1 study in HealthyNCT04840888 · 82 enrolled · United States
  4. Jul 22, 2021Phase 3 study in Breast NeoplasmsNCT04975308 · 874 enrolled · United States, Argentina, Australia and more
  5. Aug 2, 2021Phase 1 study in HealthyNCT04991766 · 16 enrolled · United States
  6. Jun 27, 20222 phase 1 studiesNCT05440344, NCT05444556
  7. Aug 19, 20222 phase 1 studiesNCT05509816, NCT05509790
  8. Aug 23, 2022Phase 3 study in Breast NeoplasmsNCT05514054 · 8,000 enrolled · United States, Argentina, Australia and more
  9. Dec 11, 2025Phase 2 study in Breast NeoplasmsNCT07287098 · 600 planned · United States, Belgium, France and more
  10. Nov 2, 2026Phase 1 study in HealthyNCT07918859 · 343 planned · United States

Ahead

  1. Aug 2027Primary completion: phase 1 study in HealthyNCT07918859
  2. Oct 2027Primary completion: phase 3 study in Breast NeoplasmsNCT05514054
  3. Jan 2029Primary completion: phase 2 study in Breast NeoplasmsNCT07287098

TargetBeta

ESR1 →read by rule
“An orally available selective estrogen receptor degrader (SERD), ”NCIt, by rule

Other programs on ESR1

ProgramCompanyFurthest phaseStudies
Ethinyl EstradiolruleJohnson & Johnsonphase 470
EstradiolruleNovo Nordiskphase 469
FulvestrantruleAstraZenecaphase 430
TamoxifenruleAstraZenecaphase 421
ClomipheneruleHamad Medicalphase 43
vepdegestrantrulePfizerphase 320
camizestrantruleAstraZenecaphase 318
giredestrantHoffmann-La Rochephase 317
HRS-8080Jiangsu HengRui Medicinephase 313
elacestrantruleMenarini Groupphase 312
taragarestrantruleInventisBiophase 35
SIM0270ruleSimcere Pharmaceutical Groupphase 35

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07918859Healthy · United States1Not yet recruitingAug 2027343
NCT07287098Breast Neoplasms · United States, Belgium, France and more2RecruitingJan 2029600
NCT05514054Breast Neoplasms · United States, Argentina, Australia and more3Active, not recruitingOct 20278,000
NCT05509816Healthy · United States1CompletedNov 30, 202220
NCT05509790Breast Neoplasms · China1Active, not recruitingFeb 18, 202417
NCT05444556Healthy · United States1CompletedNov 2, 2022113
NCT05440344Hepatic Insufficiency · United States1CompletedFeb 28, 202427
NCT04991766Healthy · United States1CompletedApr 2, 202216
NCT04975308Breast Neoplasms · United States, Argentina, Australia and more3Active, not recruitingJun 24, 2024874
NCT04840888Healthy · United States1CompletedApr 12, 202282
NCT04647487Breast Neoplasms · United States, Belgium, France and more1CompletedNov 11, 202287
NCT04188548Breast Neoplasms · United States, Australia, Belgium and more1Active, not recruitingJun 29, 2020379

How it is read

Names in the registry

  • “Imlunestrant”, 6 entries
  • “LY3484356”, 5 entries
  • “Imlunestrant (Test)”, 1 entry
  • “Imlunestrant (Reference)”, 1 entry
  • “[¹⁴C]-LY3484356”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.